Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16b-3

Slightly above 67% of Prometheus Biosciences' investor base is looking to short. The analysis of current outlook of investing in Prometheus Biosciences suggests that many traders are alarmed regarding Prometheus Biosciences' prospects. Prometheus Biosciences' investing sentiment can be driven by a variety of factors including economic data, Prometheus Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Prometheus Biosciences In director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
Prometheus insider trading alert for exercise of common stock by Mark McKenna, Chairman President CEO, on 2nd of June 2023. This event was filed by Prometheus Biosciences In with SEC on 2023-06-02. Statement of changes in beneficial ownership - SEC Form 4

Prometheus Biosciences Fundamental Analysis

We analyze Prometheus Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Prometheus Biosciences is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Prometheus Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prometheus Biosciences stock to make a market-neutral strategy. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics with similar companies.

Peers

Prometheus Biosciences Related Equities

PLRXPliant Therapeutics   4.49   
0%
79.0%
VKTXViking Therapeutics   3.06   
0%
54.0%
ACLXArcellx   1.88   
0%
33.0%
ETNB89bio   1.19   
0%
21.0%
IMVTImmunovant   0.85   
0%
15.0%
AKROAkero Therapeutics   0.40   
0%
7.0%
KRYSKrystal Biotech   0.00   
0%
0%
AMLXAmylyx Pharmaceuticals   0.94   
16.0%
0%
BPMCBlueprint Medicines   1.07   
18.0%
0%
APLSApellis Pharmaceuticals   1.25   
22.0%
0%
TERNTerns Pharmaceuticals   1.86   
32.0%
0%
ROIVRoivant Sciences   2.08   
36.0%
0%
STOKStoke Therapeutics   3.39   
59.0%
0%
DAWNDay One   4.36   
77.0%
0%
MDGLMadrigal Pharmaceuticals   5.66   
100.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets